Primary graft failure following lung transplantation.
OBJECTIVE
To determine the incidence of primary graft failure (PGF) following lung transplantation, assess possible risk factors, and characterize its effect on outcomes.


METHODS
Retrospective review of 100 consecutive patients undergoing lung transplantation at the University of Pennsylvania Medical Center. Fifteen patients meeting diagnostic criteria for PGF (PGF+ group) were compared with 85 patients without this complication (PGF- group).


RESULTS
The incidence of PGF was 15%. There was no significant difference in age, sex, underlying pulmonary disease, preoperative pulmonary artery systolic pressure, type of transplant, allograft ischemic times, use of cardiopulmonary bypass, or use of postoperative prostaglandin E1 infusion between the PGF+ and PGF- groups. Induction therapy with antilymphocyte globulin was used less frequently in the PGF+ group (p<0.005). Duration of mechanical ventilatory support was 36+/-43 days vs 4+/-6 days for the PGF+ and PGF- groups, respectively (p<0.0001). Hospital stay was significantly longer in the PGF+ group, averaging 75+/-105 days, compared with 27+/-38 days in the PGF group (p<0.005). One-year actuarial survival for the PGF+ group was only 40% compared with 69% for the PGF- group (p<0.005). Five of the six PGF+ survivors were ambulatory by 1 year; three were completely independent while two continued to require assistance with activities of daily living. Six-minute walk test distance among the ambulatory patients averaged 883+/-463 feet (range, 200 to 1,223 feet) compared with 1513+/-424 feet for the PGF- group (p<0.005). Among the subset of survivors who underwent single lung transplantation for COPD, the mean percent predicted FEV1 at 1 year was 43% for the PGF+ group and 55% for the PGF- groups, but this difference was not statistically significant.


CONCLUSIONS
PGF is a devastating postoperative complication, occurring in 15% of patients in the current series, and it is associated with a high mortality rate, lengthy hospitalization, and protracted and often compromised recovery among survivors.
Christie
J D
JD
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
Bavaria
J E
JE
Palevsky
H I
HI
Litzky
L
L
Blumenthal
N P
NP
Kaiser
L R
LR
Kotloff
R M
RM
D000203:Activities of Daily Living; D000206:Actuarial Analysis; D000367:Age Factors; D000527:Alprostadil / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D002315:Cardiopulmonary Bypass; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006085:Graft Survival; D006760:Hospitalization; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007902:Length of Stay; D008171:Lung Diseases / Q000601:surgery; D008173:Lung Diseases, Obstructive / Q000601:surgery; D016040:Lung Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011651:Pulmonary Artery; D012121:Respiration, Artificial; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D000527:Alprostadil